Life Sciences Cybersecurity & Risk Management

Life sciences organizations handle high-value intellectual property, clinical trial data, and protected health information (PHI) that make them prime targets for cyberattacks. Unlike other industries, a cybersecurity breach in life sciences can directly impact patient safety, delay drug approvals, disrupt manufacturing of critical medications, and trigger regulatory enforcement actions under FDA, HIPAA, and EU NIS2 requirements.

The threat landscape facing life sciences in 2026 has grown both broader and more severe. Ransomware attacks targeting manufacturing and clinical systems continue to rise — up 37% year-over-year per the 2025 Verizon DBIR — but financially-motivated ransomware is no longer the only destructive threat to plan for. Nation-state and hacktivist actors are increasingly deploying wiper attacks designed to destroy data and disable operations rather than demand payment, as demonstrated by the March 2026 cyberattack on medtech giant Stryker, in which an Iran-linked group claimed to have wiped over 200,000 devices across 79 countries in a single incident. Other major threat vectors include identity-based attacks targeting researcher and regulatory credentials through AI-enhanced phishing campaigns, third-party supply chain breaches through CROs and CDMOs, cloud misconfigurations exposing sensitive research data, shadow AI usage leaking proprietary information into public models, and AI-powered attacker tooling that enables faster, more convincing, and harder-to-detect intrusion campaigns. Life sciences companies must address both IT and operational technology (OT) vulnerabilities — and build resilience against adversaries whose goal is disruption, not just extortion.

A virtual Chief Information Security Officer provides strategic cybersecurity leadership without the cost of a full-time executive hire. For life sciences companies, a vCISO develops cybersecurity strategies aligned with GxP compliance, manages regulatory requirements across FDA, HIPAA, and global frameworks, oversees third-party risk management, and leads incident response planning — all with deep understanding of life sciences-specific regulatory and operational requirements.

Cybersecurity and GxP compliance are deeply interconnected. 21 CFR Part 11 requires electronic records and signatures to be trustworthy, reliable, and protected from unauthorized access — which demands robust access controls, audit trails, data encryption, and validated security systems. A cybersecurity program that doesn’t account for GxP requirements creates compliance gaps, while a GxP program without strong cybersecurity leaves regulated systems vulnerable to threats.

Life sciences companies face a layered and rapidly evolving regulatory landscape. For medical device manufacturers, the FDA’s June 2025 final guidance — Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions — is now binding under Section 524B of the FD&C Act, requiring mandatory Software Bills of Materials (SBOMs), continuous vulnerability management, and comprehensive premarket cybersecurity documentation. Noncompliance can now result in denied market authorization. Separately, for pharmaceutical and biotech manufacturers, the FDA issued a June 2025 OT cybersecurity white paper — Securing Technology and Equipment Used for Medical Product Manufacturing — recommending that companies secure connected operational technology across production environments, aligned to NIST and CISA frameworks. This white paper is advisory rather than a formal regulatory mandate, but it signals clear FDA direction on manufacturing cybersecurity expectations. Beyond FDA, HIPAA governs protection of patient data; the EU NIS2 Directive — now transposed into member state law across the EU and in force since late 2024 — classifies healthcare and pharmaceutical manufacturing as “essential” sectors with mandatory incident reporting and risk management obligations; and GDPR applies to any personal data processed in connection with EU individuals. Industry frameworks including NIST CSF 2.0 and ISO 27001 provide the underlying control structure most regulators and auditors expect. Companies operating globally must navigate these overlapping requirements across multiple jurisdictions — a complexity that makes a vCISO with regulatory depth particularly valuable.

Third-party breaches now account for 30% of all data breaches (Verizon DBIR 2025). Life sciences companies should implement a tiered risk model prioritizing CROs, CDMOs, and cloud providers as highest-risk vendors. Key practices include requiring SOC 2 Type II or ISO 27001 certification, adding cybersecurity clauses to all contracts, conducting regular security assessments of critical vendors, issuing time-bound access credentials, and continuously monitoring vendor security posture.

Zero trust is a security model that requires continuous verification of every user, device, and connection — regardless of network location. Rather than assuming anything inside the perimeter is trustworthy, zero trust operates on the principle of least-privilege access, microsegmentation, and continuous authentication. For regulated life sciences environments, this architecture directly supports GxP compliance by enforcing granular access controls to clinical and manufacturing systems, enabling segmentation of lab and OT networks, and generating the detailed audit trails that regulatory reporting requires. Zero trust also limits lateral movement if a breach occurs — reducing the blast radius of an intrusion that would otherwise traverse from a compromised endpoint to validated systems. The FDA’s 2025 OT cybersecurity white paper reinforces CISA and NIST frameworks that align directly with zero trust principles — including network segmentation, least-privilege access, and continuous monitoring in manufacturing environments — making zero trust a natural architectural expression of where pharmaceutical manufacturing security expectations are heading.

AI is transforming drug discovery, clinical development, and manufacturing — but it introduces a distinct set of cybersecurity and IP risks that most life sciences companies are not yet fully managing. The most immediate exposure is shadow AI: employees using public generative AI tools and inadvertently submitting proprietary research, clinical protocols, or regulatory documents as prompts, effectively transferring sensitive IP outside the organization’s control with no audit trail and no security alert. A deeper risk involves AI training data — pharma and biotech companies building models for drug discovery often train them on proprietary datasets derived from patient-level data or clinical trial results, and if those environments are compromised, breach notification obligations under HIPAA or GDPR may be triggered with the added complication of being unable to identify exactly whose data was affected.. Addressing these risks requires a governance response as much as a technical one: classifying AI tools within your TPRM program, implementing data loss prevention controls covering generative AI usage, establishing acceptable use policies before adoption outpaces oversight, and ensuring AI systems handling regulated data are validated and access-controlled consistent with GxP requirements.